Press release
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market to Advance at Moderate CAGR During the Forecast Period (2023-2032) - Estimates DelveInsight | Regeneron, AstraZeneca, Hinova Pharma, Eli Lilly, Astellas Pharma, Seagen, Pfizer, Progenics
The market report covers emerging drugs, treatment practices, market share of individual Metastatic Castration-Resistant Prostate Cancer therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Metastatic Castration-Resistant Prostate Cancer treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.
Metastatic Castration-Resistant Prostate Cancer (mCRPC): An Overview
Prostate cancer is a type of malignancy that occurs in the prostate gland. It is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm. However, in 6-10% of cases, cancer has spread to parts of the body farther from the prostate, such as the lungs, liver, or bones, and is known as distant or metastatic prostate cancer.
Castration-resistant prostate cancer (CRPC) is a form of advanced prostate cancer. With mCRPC, the cancer no longer completely responds to treatments that lower testosterone, and it is found in other parts of the body. It shows signs of growth, like a rising PSA (prostate-specific antigen), even with low levels of testosterone. Metastatic CRPC is associated with a poor prognosis and reduced survival. The estimated 5-year survival rate for men with metastatic prostate cancer is around 30% compared to 100% survival in men with localized prostate cancer
Discover How Metastatic Castration-Resistant Prostate Cancer Market Will Grow by 2032:
https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Metastatic Castration-Resistant Prostate Cancer therapies in the market. It also provides a detailed assessment of the Metastatic Castration-Resistant Prostate Cancer market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the market trend for each marketed Metastatic Castration-Resistant Prostate Cancer drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Epidemiology
The epidemiology section covers detailed insights into the historical, and current Metastatic Castration-Resistant Prostate Cancer patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.
The Report Covers the Metastatic Castration-Resistant Prostate Cancer Epidemiology Segmented as -
Total Prevalent Cases of Prostate Cancer in the 7MM (2019-2032)
Total Treated Cases of Metastatic CRPC in the 7MM (2019-2032)
Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM (2019-2032)
Total Diagnosed Cases of Prostate Cancer in the 7MM (2019-2032)
Total Metastatic Cases of CRPC in the 7MM (2019-2032)
Get Key Insights Into the Evolving Metastatic Castration-Resistant Prostate Cancer Epidemiology Trends @
https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Castration-Resistant Prostate Cancer market or expected to be launched during the study period. The analysis covers the market share by Metastatic Castration-Resistant Prostate Cancer drugs, patient uptake by therapies, and sales of each drug.
The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.
The report also covers the Metastatic Castration-Resistant Prostate Cancer Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Therapeutics Assessment
The treatment paradigm of mCRPC is full of competition as many of the approved therapies are already present in the market and many of the therapies are present in the pipeline for fulfilling the unmet needs in mCRPC treatment.
The dynamics of the mCRPC market are anticipated to change in the coming years owing to the rise in the number of companies taking interest in the development of specific drugs for mCRPC along with increasing awareness and penetration of already approved prostate cancer drugs in mCRPC.
Leading Companies in the Metastatic Castration-Resistant Prostate Cancer (mCRPC) Therapeutics Market Include
Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, among others
Emerging and Marketed Metastatic Castration-Resistant Prostate Cancer (mCRPC) Therapies Covered in the Report Include
• Abemaciclib (LY2835219): Eli Lilly and Company
• 177Lu-PSMA-617: Novartis
• AZD4635: AstraZeneca
• Capivasertib (AZD5363): AstraZeneca
• EPI-7386: ESSA Pharmaceuticals
• Erleada (apalutamide): Janssen Pharmaceutical
• HC-1119: Hinova Pharmaceuticals
• HP518: Hinova Pharmaceuticals
• Ipatasertib (RG7440): Hoffmann-La Roche
• Jevtana (Cabazitaxel): Sanofi
• Keytruda (Pembrolizumab/MK-3475): Merck Sharp & Dohme
• LAE001: Laekna Therapeutics
• Lynparza (Olaparib): AstraZeneca/ Merck Sharp & Dohme
• Niraparib: Janssen Research & Development
• ODM-208: Orion Pharma
• Opdivo (nivolumab): Bristol-Myers Squibb
• Onvansertib: Cardiff Oncology
• Proxalutamide (GT0918): Suzhou Kintor Pharmaceutical
• Rubraca (Rucaparib): Clovis Oncology
• Rucaparib: Clovis Oncology
• Sacituzumab Govitecan (IMMU-132): Immunomedics
• SRF617: Surface Oncology
• Talazoparib: Pfizer/Astellas Pharma
• Xtandi (Enzalutamide): Astellas Pharma
• Xofigo (radium Ra 223 dichloride): Bayer Health Care
And Many More
Learn More About the Emerging Therapies & Key Companies in the Metastatic Castration-Resistant Prostate Cancer Therapeutics Market:
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Metastatic Castration-Resistant Prostate Cancer Competitive Intelligence Analysis
4. Metastatic Castration-Resistant Prostate Cancer Market Overview at a Glance
5. Metastatic Castration-Resistant Prostate Cancer Background and Overview
6. Metastatic Castration-Resistant Prostate Cancer Patient Journey
7. Metastatic Castration-Resistant Prostate Cancer Epidemiology and Patient Population
8. Metastatic Castration-Resistant Prostate Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Metastatic Castration-Resistant Prostate Cancer Unmet Needs
10. Key Endpoints of Metastatic Castration-Resistant Prostate Cancer Treatment
11. Metastatic Castration-Resistant Prostate Cancer Marketed Products
12. Metastatic Castration-Resistant Prostate Cancer Emerging Therapies
13. Metastatic Castration-Resistant Prostate Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Metastatic Castration-Resistant Prostate Cancer Market Outlook (7 major markets)
16. Metastatic Castration-Resistant Prostate Cancer Access and Reimbursement Overview
17. KOL Views on the Metastatic Castration-Resistant Prostate Cancer Market.
18. Metastatic Castration-Resistant Prostate Cancer Market Drivers
19. Metastatic Castration-Resistant Prostate Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/metastatic-castration-resistant-prostate-cancer-mcrpc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market to Advance at Moderate CAGR During the Forecast Period (2023-2032) - Estimates DelveInsight | Regeneron, AstraZeneca, Hinova Pharma, Eli Lilly, Astellas Pharma, Seagen, Pfizer, Progenics here
News-ID: 3425271 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Prostate
The 3D Urology and Prostate Clinics Introduces Innovative Natural and Targeted P …
The 3D Urology and Prostate Clinics introduces its innovative 3D targeted injection therapies, offering effective, natural solutions for various prostate conditions including prostatitis, enlarged prostate, and prostate cancer.
Renowned for its pioneering approach to prostate health, The 3D Urology and Prostate Clinics is bringing renewed hope to patients worldwide suffering from various prostate diseases. Utilizing advanced diagnostic techniques and a unique targeted injection method, the clinics offer specialized treatments that focus…
The 3D Urology and Prostate Clinics Introduces Advanced 3D Prostate Targeted Tre …
The 3D Urology and Prostate Clinics announces its latest breakthrough in targeted prostate treatment, offering a revolutionary approach to prostate cancer and other prostate-related conditions.
The 3D Urology and Prostate Clinics, renowned for its advanced techniques in prostate health, is proud to present its groundbreaking 3D prostate Targeted Treatment, a comprehensive and non-invasive solution for men suffering from prostate conditions. The clinic's innovative treatment is designed to target the root causes…
The 3D Urology and Prostate Clinics Unveil Innovative 3D Prostate Targeted Treat …
The 3D Urology and Prostate Clinics introduce their groundbreaking 3D prostate targeted treatment, offering a non-invasive solution for prostate health issues.
The 3D Urology and Prostate Clinics, renowned for their specialized treatments in prostate health, are proud to unveil their innovative 3D prostate targeted treatment. This cutting-edge therapy provides a non-invasive, highly effective solution for prostate-related conditions, offering patients a new path to recovery and well-being.Image: https://i.imgur.com/NCfbb6S.jpg
At the heart of this…
The 3D Urology and Prostate Clinics Unveils Advanced 3D prostate Targeted Treatm …
The 3D Urology and Prostate Clinics is at the forefront of prostate care, offering the advanced 3D Targeted Therapy as a precise and effective treatment solution.
The 3D Urology and Prostate Clinics is proud to announce its revolutionary 3D prostate Targeted Treatment [http://www.3dprostatecure.com/page.php?cata_id=19], setting a new standard in prostate care. This highly advanced treatment option utilizes cutting-edge technology to deliver focused treatment, minimizing side effects and enhancing recovery for patients. Men…
3D Prostate Cure: Revolutionizing Prostate Treatment with Targeted Therapy
This news release highlights the 3D Urology and Prostate Clinics' innovative approach to prostate treatment using 3D Targeted Therapy, offering a safe and effective alternative to traditional methods.
As a global leader in men's health, The 3D Urology and Prostate Clinics is committed to providing cutting-edge treatments for various prostate conditions. The clinic is proud to announce its revolutionary 3D Targeted Therapy, offering a new standard in prostate care.
This innovative therapy…
The 3D Urology and Prostate Clinics Enhance Prostate Health with Advanced 3D Pro …
The 3D Urology and Prostate Clinics are revolutionizing prostate care with their comprehensive treatments, including the 3D prostate Targeted Treatment and 3D Targeted Therapy, developed to ensure effective, non-surgical solutions for prostate health issues.
At the forefront of prostate health, The 3D Urology and Prostate Clinics are excited to offer innovative treatments such as the 3D prostate Targeted Treatment and 3D Targeted Therapy. These treatments are part of the clinic's commitment…
